Angiochem is a biotech company discovering and developing medications that are crossing the blood-brain barrier (BBB) to treat brain diseases. It focuses on peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological disorders. The company uses small molecules and biologics to address a range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases, and pain.